Literature DB >> 29249770

Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report.

Hiroaki Komatsu1, Nobuhiro Izumi1, Takuma Tsukioka1, Michihito Toda1, Kantaro Hara1, Hikaru Miyamoto1, Noritoshi Nishiyama1.   

Abstract

A 66-year-old woman underwent right nephrectomy for treatment of renal cell carcinoma (RCC). Two years later, she underwent wedge resection of the right lung for treatment of metastatic RCC and primary adenocarcinoma of the lung. She began oral sorafenib for the remaining nodules of the left lung, which were suspected to be metastatic RCC. Two years later, the sorafenib was changed to everolimus because of slight enlargement of the left pulmonary nodules. The carcinoembryonic antigen (CEA) concentration then increased to 25.7 ng/mL, and chest computed tomography (CT) revealed ground-glass opacities (GGO) in the bilateral lungs. Everolimus-induced lung injury was suspected, and she discontinued the everolimus. Two months later, the serum CEA concentration decreased to almost within the reference range at 5.9 ng/mL, and the GGO disappeared on chest CT. In conclusion, we encountered a patient who developed an elevated serum CEA concentration caused by everolimus-induced lung injury.

Entities:  

Keywords:  carcinoembryonic antigen; drug-induced lung injury; everolimus; tumor marker

Mesh:

Substances:

Year:  2017        PMID: 29249770      PMCID: PMC6033529          DOI: 10.5761/atcs.cr.17-00092

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  11 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis.

Authors:  Kira H Bramswig; Marina Poettler; Matthias Unseld; Friedrich Wrba; Pavel Uhrin; Wolfgang Zimmermann; Christoph C Zielinski; Gerald W Prager
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis.

Authors:  Ahmed Fahim; Michael G Crooks; Rachel Wilmot; Anne P Campbell; Alyn H Morice; Simon P Hart
Journal:  Respirology       Date:  2012-11       Impact factor: 6.424

4.  Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Authors:  E Seront; S Rottey; B Sautois; J Kerger; L A D'Hondt; V Verschaeve; J-L Canon; C Dopchie; J M Vandenbulcke; N Whenham; J C Goeminne; M Clausse; D Verhoeven; P Glorieux; S Branders; P Dupont; J Schoonjans; O Feron; J-P Machiels
Journal:  Ann Oncol       Date:  2012-04-03       Impact factor: 32.976

Review 5.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.

Authors:  M Grunnet; J B Sorensen
Journal:  Lung Cancer       Date:  2011-12-06       Impact factor: 5.705

Review 6.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

7.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

8.  Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer.

Authors:  Naoki Ozeki; Takayuki Fukui; Tetsuo Taniguchi; Noriyasu Usami; Koji Kawaguchi; Simon Ito; Yukinori Sakao; Tetsuya Mitsudomi; Akihiro Hirakawa; Kohei Yokoi
Journal:  Eur J Cardiothorac Surg       Date:  2013-08-26       Impact factor: 4.191

9.  Drug-induced Pneumonitis Following the Administration of TAS-102.

Authors:  Yoshikazu Hasegawa; Takayo Ota; Hiroshi Tsukuda; Tomohiro Suzumura; Masahiro Fukuoka
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

10.  Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.

Authors:  Sinead A Noonan; Peter B Sachs; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-09-13       Impact factor: 15.609

View more
  2 in total

1.  Comment on "Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report".

Authors:  Hiroshi Nomoto; Hideaki Miyoshi; Tomonori Sekizaki; Tatsuya Atsumi
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-03-16       Impact factor: 1.520

2.  Serum carcinoembryonic antigen elevation in benign lung diseases.

Authors:  Yi Yang; Mingfang Xu; Huan Huang; Xiaolin Jiang; Kan Gong; Yun Liu; Xunjie Kuang; Xueqin Yang
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.